Αποτελέσματα Αναζήτησης
19 Ιουν 2023 · Triple-negative breast cancer (TNBC) is a very heterogeneous and aggressive breast cancer subtype with a high risk of mortality, even if diagnosed early. The mainstay of early-stage breast cancer includes systemic chemotherapy and surgery, with or without radiation therapy.
29 Μαΐ 2024 · The treatment landscape for early-stage TNBC has changed considerably in the last decade, with new additions to neoadjuvant therapy (NAT) aimed at improving pathologic responses and outcomes. In this study, we assess real world data regarding treatment and outcomes in those with early-stage TNBC.
15 Φεβ 2023 · Adjuvant chemotherapy showed a consistent survival benefit with improved DFS in breast cancer and has shown a greater survival benefit in TNBC than in hormone receptor (HR)-positive breast cancer . Traditional adjuvant chemotherapy is based on anthracyclines, taxanes, and alkylating agents.
1 Ιουν 2018 · Meta-regression analysis explored the influence of study-level median follow-up, tumor size, nodal status, median age, menopausal status and generation of chemotherapy on the benefit from adjuvant chemotherapy. Results: Nineteen studies comprising of 22 comparison groups and 11306 patients with TNBC were included in the analysis.
1 Αυγ 2012 · Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Clin Oncol. 2010; 28:2966-2973.
11 Ιαν 2022 · Many effective treatments for most breast cancers block the growth-stimulating effects of ER, PR, and/or HER2, leaving TNBC with few choices. Finding new and effective treatment options for TNBC remains a critical clinical need.
30 Νοε 2020 · We investigated if breast cancer-specific survival (BCSS; which excludes deaths unrelated to breast cancer) and OS are improved when women with TNBC aged 70 years and older are treated with adjuvant chemotherapy.
